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Abstract
Background: Much attention has been focused on the design and synthesis of potent, cationic antimicrobial peptides
(AMPs) that possess both antimicrobial and anti-inflammatory activities. However, their development into therapeutic
agents has been limited mainly due to their large size (12 to 50 residues in length) and poor protease stability.
Methodology/Principal Findings: In an attempt to overcome the issues described above, a set of ultra-short, His-derived
antimicrobial peptides (HDAMPs) has been developed for the first time. Through systematic tuning of pendant hydrophobic
alkyl tails at the N(p)- and N(t)-positions on His, and the positive charge of Arg, much higher prokaryotic selectivity was
achieved, compared to human AMP LL-37. Additionally, the most potent HDAMPs showed promising dual antimicrobial and
anti-inflammatory activities, as well as anti–methicillin-resistant Staphylococcus aureus (MRSA) activity and proteolytic
resistance. Our results from transmission electron microscopy, membrane depolarization, confocal laser-scanning
microscopy, and calcein-dye leakage experiments propose that HDAMP-1 kills microbial cells via dissipation of the
membrane potential by forming pore/ion channels on bacterial cell membranes.
Conclusion/Significance: The combination of the ultra-short size, high-prokaryotic selectivity, potent anti-MRSA activity,
anti-inflammatory activity, and proteolytic resistance of the designed HDAMP-1, -3, -5, and -6 makes these molecules
promising candidates for future antimicrobial therapeutics.
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Introduction
Antibiotics play an important role in preventing and treating
diseases. However, excessive use of antibiotics has resulted in
many emerging multidrug-resistant microorganisms; thus, antibi-
otic resistance has become a global public health problem. The
emergence of multidrug-resistant bacteria and the low discovery
rate of conventional antibiotics have resulted in an urgent need for
developing new antimicrobials. Antimicrobial peptides (AMPs) are
integral components of the innate host defense mechanism in
many organisms, such as plants, insects, amphibians, and
mammals. AMPs are generally 12 to 50 amino acids in length,
contain excess positively charged amino acids (lysine and arginine
residues) and around 50% hydrophobic amino acids, and fold into
a diversity of amphipathic structures upon contact with microbial
membranes [1–5]. They are emerging as a promising new
generation of antibiotics because of their rapid and broad-
spectrum antimicrobial properties, their ability to kill multidrug-
resistant bacteria, and their low propensity for developing
resistance [6,7]. Although other mechanisms of action have been
proposed, the bacterial killing effect of the majority of AMPs, such
as melittin and LL-37, is considered to be because of their action
on the lipid matrix of bacterial cell membranes, either by forming
pores, thinning the membrane, or destabilizing the bilayer (i.e. the
membrane-targeting AMPs) [8–10]. These mechanisms of action
cause the lysis of bacterial cells as a result of increased
permeability. In contrast, a few peptides, such as buforin-2 and
PR-39, were known to penetrate microbial cell membranes
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without inducing membrane permeabilization, and cause bacterial
cell death by inhibiting protein, DNA, or RNA synthesis (i.e. the
intracellular-targeting AMPs) [11–13]. Moreover, AMPs also
regulate the pro- and anti-inflammatory cytokine expression to
modulate immune response by controlling the balance between
inducing inflammation, and at the same time protecting the
organism from the detrimental effects of excessive inflammatory
response. For instance, apart from their direct antimicrobial
activity, some cathelicidin-derived AMPs, including LL-37, CAP-
18, SMAP-29, indolicidin, bactenecin, and b-defensin, are
reported to have the ability to sequester lipopolysaccharide (LPS)
and effectively neutralize its toxicity. This endotoxin is released
from the bacteria during cell division or cell death, or, in
particular, because of antibiotic therapy against bacterial infection
[14]. Despite the many attractive properties of AMPs, their
pharmaceutical development into therapeutic agents has been
limited because of their large size, which poses several issues,
including high production cost, poor protease stability, potential
immunogenicity, and toxicity. A key strategy for resolving these
problems is to design and synthesize shorter peptides with unusual
amino acids, which capture the essential biological properties of
AMPs. Several approaches are also being pursued to make shorter
peptides [15–18], including cyclic peptides [19–21], non-natural
peptidomimetics such as peptoids [4,22–25], b-peptides [26–29],
arylamide oligomers [30–31], c-peptides [32], oligo-acyl lysines
[33,34], oligourea [35], and lipopeptides [36–38]. However,
despite significant enthusiasm, there are intrinsic drawbacks
associated with water solubility, complicated synthetic route, and
difficulty of introducing a variety of functional groups to fine tune
their activity and selectivity.
Therefore, in the present work, we focused on developing ultra-
short AMPs (two or three residues in length) having dual
antimicrobial and anti-inflammatory activities. A series of His-
derived AMPs (HDAMPs) composed of one histidine (His)
derivative with hydrophobic alkyl tails and one or two Arg
residues were designed and synthesized. The solid-phase synthesis
of HDAMPs is straightforward, using our His-derived amino
acids, and they have a high potential for diversification at a
relatively low cost. The prokaryotic selectivity of the designed
HDAMPs was investigated by examining their antimicrobial
activity against both Gram-positive and Gram-negative bacterial
strains, and their hemolytic activity against human red blood cells
(hRBCs). The anti-inflammatory activity of the designed
HDAMPs was evaluated by examining inhibition of nitric oxide
(NO) and tumor necrosis factor-a (TNF-a) production in LPS-
stimulated mouse macrophage RAW 264.7 cells. The LPS-
neutralizing activity of the designed HDAMPs was examined by
the chromogenic limulus amebocyte lysate (LAL) assay. In order to
identify the most promising, cost-effective ultra-short AMPs as a
drug candidate, the designed HDAMPs were compared in terms
of (i) broad-spectrum antimicrobial activity, (ii) prokaryotic
selectivity, (iii) anti-inflammatory activity, (iv) anti-methicillin-
resistant Staphylococcus aureus (MRSA) activity, and (v) protease
stability. Finally, the molecular mechanism of antimicrobial
activity was investigated by transmission electron microscopy
(TEM), confocal laser-scanning microcopy, calcein-dye leakage,
and membrane depolarization experiments. To the best of our
knowledge, this is the first study that demonstrates effective and
ultra-short HDAMPs (two or three residues in length) of
antimicrobial agents having dual functions of antimicrobial and
anti-inflammatory activities.
Results
Design and synthesis of Trp/Arg-rich and His-derived
antimicrobial peptides (HDAMPs)
As a part of our continuing efforts to search for an inherently
simple scaffold to pin down the importance of hydrophobicity and
charge on antimicrobial activity, we have envisioned the use of His
derivatives to capture the structural and biological properties of
AMPs. A key feature in the design of these HDAMPs was the first-
time isolation and purification of the Fmoc-protected His
derivative, with pendant alkyl tails at the N(p)- and N(t)- positions
and bearing diverse structural variations, and the application of
this derivative into the synthesis of antimicrobial peptides [39].
Briefly, the synthesis of Fmoc-protected His derivatives was
preceded by a three-step synthesis method using commercially
available Fmoc-His(Trt)-OH as a starting material. First, the
esterification of Fmoc-His(Trt)-OH was efficiently carried out
using dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotria-
zole (HOBt) as coupling agents in the presence of methanol.
Second, the dialkylation at the N(p)- and N(t)- positions on Fmoc-
His(Trt)-OMe was proceeded using two equivalents of corre-
sponding alcohol in the presence of triflic anhydride and DIEA.
Finally, the acid hydrolysis of ester produced the expected Fmoc-
protected, dialkylated His derivatives in good yield (Figure 1).
Next, the above synthesized N(p)-alkyl and N(t)-alkyl bis-adducted
His monomers were successfully used to generate our focused
peptide library, including seven HDAMPs using Rink amide resin
by the conventional solid-phase peptide synthesis (Figure 1,
Figure 2).
A series of Trp (W)/Arg (R)–rich peptides [(WR)3-NH2, (WR)2-
NH2 and RWR-NH2], reported as being short and potent
antimicrobial peptides [40], were used as sequence templates,
and their antimicrobial and hemolytic activities were compared to
seven HDAMPs (Figure 2). Matrix-assisted laser-desorption
ionization time-of-flight mass spectrometry (MALDI-TOF MS)
was used to verify the molecular weight of both Trp/Arg-rich
AMPs and the seven HDAMPs. Human cathelicidin LL-37, a
potent antimicrobial and anti-inflammatory peptide, served as a
positive control for comparing the antimicrobial, hemolytic, and
anti-inflammatory activities. The hydrophobicity of all of the
peptides was measured with the use of reverse-phase high-
performance liquid chromatography (RP-HPLC) retention time
(Rt).
Antimicrobial and hemolytic activities and prokaryotic
selectivity
All of the peptides were assayed for their antimicrobial activities
towards two Gram-negative bacteria (Escherichia coli and Pseudomonas
aeruginosa) and two Gram-positive bacteria (Staphylococcus epidermidis
and Staphylococcus aureus). The prokaryotic selectivity of the peptides
to mammalian cells was determined by measuring their hemolytic
activity toward hRBCs, as described previously in our study
(Table 1) [41].
The therapeutic potential of antimicrobial agents lies in their
prokaryotic selectivity to effectively kill bacterial cells without
exhibiting significant cytotoxicity toward mammalian cells. The
prokaryotic selectivity of our designed HDAMPs is defined by the
therapeutic index (TI) as a measure of the relative safety of the
drug. It is a measure of a peptide’s capability to differentiate any
pathogen from a host cell. The TI value of each peptide was
calculated as the ratio of the HC10 (the peptide concentration that
produces 10% hemolysis toward hRBCs) to the geometric mean
[GM; the geometric mean of the minimal inhibitory concentration
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(MIC) against four selected bacterial strains]. Larger values of TI
correspond to greater prokaryotic selectivity.
Structure-antimicrobial and hemolytic activities studies
Correlation between Trp/Arg-rich AMPs and
HDAMPs. The MICs obtained for the (WR)3-NH2 (4–16 mg/
mL) was lower than that of LL-37, whereas the (WR)2-NH2,
having two repeating WR units, showed an eight times decrease in
antimicrobial activity; finally, the removal of one Trp unit from
the (WR)2-NH2 (MIC:.64 mg/mL) at the N-terminal gave rise to
a complete loss of antimicrobial activity. In contrast, all of the
Trp/Arg-rich AMPs showed no hemolytic activity even at the
highest concentration (256 mg/mL) tested. (Table 1, Figure 2).
Based on the results described above, we designed and
synthesized both tripeptide and tetrapeptide HDAMPs (Arg-
His((CH2)7C6H5)2-Arg-NH2) and His((CH2)7C6H5)2-Arg-
His((CH2)7C6H5)2-Arg-NH2) (Figure 2), and tested the antimicro-
bial activity. Our assay results showed that the tetrameric
HDAMP did not show any measurable antimicrobial activity at
a concentration as high as 200 mg/mL (Table 1), whereas the
shorter tripeptide, HDAMP-1, displayed one of the most potent
short HDAMPs reported to date, with the MIC value of around 2–
4 mg/mL against the bacterial strains (Table 1). Surprisingly, the
activity of HDAMP-1 against P. aeruginosa and S. epidermidis was
four times higher than the highly potent Trp/Arg-rich (WR)3-NH2
peptide. Although HDAMP-1 showed hemolytic activity, the TI
(10.3) was two times higher than the TI of LL-37 (4.7; Table 1).
Length of hydrocarbon tail
Next, to investigate the effect of the hydrocarbon tail length on
antimicrobial activity, we decreased the length of the hydrocarbon
tail from C-7 to C-3 (HDAMP-2). A small decrease (two- or four-
fold) in the antimicrobial activity of HDAMP-2 was observed.
However, HDAMP-2 displayed a higher TI value than HDAMP-
1 because HDAMP-2 was non-hemolytic even at the high
concentration of 256 mg/mL. This result suggests that the
hemolytic activity (HC10 values) increased with an increase in
the pendant alkyl tail length from C3 to C7 (Table 1, Figure S1).
Charge
To understand the role of charge on HDAMPs in antimicrobial
activity, we derived dipeptide HDAMP-3 by the N-terminal
deletion of Arg and analyzed the antimicrobial activity. Encour-
agingly, dipeptide HDAMP-3 also displayed similar activity
against Gram-negative bacteria, and it was even more active
against Gram-positive, S. aureus bacteria in comparison to
tripeptide peptide, HDAMP-1 (Table 1). This indicates that the
lipophilicity of the pendant alkyl tails on HDAMPs was critical,
and that the decreased cationic property resulting from the
deletion of Arg at the N-terminus did not affect antimicrobial
activity, but gave a two-fold decrease in the TI value due to the
increased hemolytic activity (Table 1, Figure S1).
Figure 1. Synthetic protocol of Fmoc-His-OH derivatives and tripeptide HDAMP-1 using solid-phase peptide synthesis.
doi:10.1371/journal.pone.0080025.g001
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Hydrophobicity
The higher activity and selectivity of HDAMP-1 and -3 could
be because of the existence of a delicate balance between the
charge density and hydrophobicity. This prompted us to further
evaluate the effect of hydrophobicity independently of length by
comparing dialkylated HDAMP-1 to N(p)-monoalkylated peptide,
Figure 2. The structures of His-derived antimicrobial peptides (HDAMPs) and Trp/Arg-rich peptides were tested for their
antimicrobial activity.
doi:10.1371/journal.pone.0080025.g002
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HDAMP-4 (Figure 2). The assay results showed that the
hydrophobicity played an important role in antimicrobial activity
against Gram-negative bacteria (E. coli and P. aeruginosa) because it
showed an eight-fold decrease in activity when compared to
HDMP-1. On the other hand, the activity towards the Gram-
positive bacteria was not significantly affected (Table 1).
Potency of D-Arg-substituted HDAMPs
D-amino acid forms of the peptides are well known for
enhancing the stability and exploiting the specificity of proteases
for L-amino acid forms. But the incorporation of D-amino acids in
certain AMPs has caused considerable reduction in the activity
when compared to the original L-amino acid peptide [42].
Considering the importance of our His-derived residues in
providing potent antimicrobial activity, we synthesized the
tripeptide HDAMP-5 and dipeptide HDAMP-6, in which the L-
Arg of HDAMP-1 and HDAMP-3 was substituted by the
corresponding D-form of Arg, respectively (Figure 2). HDAMP-5
showed a four-fold decrease in antimicrobial activity, but no
hemolytic activity (HD10:.256 mg/mL, Figure S1). On the other
hand, HDAMP-6 retained the antimicrobial activity of the original
HDAMP-3, which had the L-amino acid, along with a slight
increase in the prokaryotic selectivity (Table 1).
Overall, the results described above confirmed that the
HDAMPs covered the broad spectrum of antimicrobial activity
in comparison to at least Trp/Arg-rich AMPs (Table 1, Figure 2).
Studies on anti-inflammatory activity
After establishing the potent antimicrobial activity using our
HDAMPs, next, we investigated the anti-inflammatory activity.
Here, we evaluated the anti-inflammatory activity of our designed
ultra-short HDAMPs by examining the inhibition of NO and
TNF-a production in LPS-stimulated RAW264.7 cells, as well as
from the direct inhibition of LPS.
First, to compare the relative anti-inflammatory activity of the
designed peptides, the inhibition assay for NO production in LPS-
stimulated RAW264.7 cells was performed at the concentration of
8 mg/mL (Figure 3A). Among the designed ultra-short HDAMPs,
HDAMP-1, -3, -5, and -6 significantly inhibited LPS-induced NO
production. Encouragingly, HDAMP-1 showed similar inhibition
of NO production compared to LL-37, a known naturally
occurring AMP with potent anti-inflammatory activity. Moreover,
as evidenced by the dose-dependent, LPS-induced NO production
inhibition (Figure 3B), HDAMP-1 showed significant inhibitory
activity at the concentration of 4 mg/mL, corresponding to its
MIC value. In contrast, HDAMP-2 and -4 displayed no NO
production inhibition at 8 mg/mL, when compared to HDAMP-1.
Interestingly, one of the tripeptide HDAMP-5, differing in the
isomeric variation of Arg as compared to HDAMP-1, showed 60%
NO production inhibition in LPS-stimulated RAW264.7 cells
(Figure 3B).
A large body of evidence showed that TNF-a was the major
mediator in endotoxic shock. We studied the inhibition of TNF-a
released by LPS-stimulated macrophages in a dose-dependent
manner using our HDAMPs and evaluated their endotoxin-
neutralizing activity [43]. In contrast to NO production inhibition,
only HDAMP-1 showed significant reduction of TNF-a release,
which was similar to LL-37, whereas the other HDAMPs, such as
3, 5, and 6, were less active (Figure 3C). At the concentration of
16 mg/mL, HDAMP-1 increased the reduction of TNF-a release
two-fold when compared to LL-37, whereas the 8 mg/mL of the
peptide concentration was sufficient to exert a similar blockage of
TNF-a by LL-37 (Figure 3D). Since the studies described above
showed that HDAMP-1, -3, -5, and -6 effectively inhibited LPS-
induced NO or TNF-a production in RAW264.7 cells, we asked
whether these HDAMPs could directly block the binding of LPS.
The concentration-response curve for LPS binding was evaluated
in the presence of these HDAMPs and LL-37 by the LAL assay
(Figure 4). The assay result showed that HDAMP-1 ( ) and
HDAMP-3 (#) had similar binding affinities when compared to
LL-37 (&), whereas HDAMP-5(m) and -6 (D), having D-isoform
of Arg, had little effect on LPS interactions (Figure 4). Consistent
with this observation, these peptides did not significantly inhibit
LPS-induced TNF-a production. Thus, the ability of the
HDAMPs to inhibit LPS interactions depends on structural
features in addition to their positive charges. Overall, the ability of
different HDAMPs, such as 1, 3, 5, and 6, to inhibit LPS-
stimulated NO or TNF-a production correlated well with their
ability to block LPS binding.
Antimicrobial activity against MRSA
The annual frequency of deaths from MRSA, a major cause of
skin and soft-tissue infections in hospitals, is rapidly increasing and
is greater than those caused by human immunodeficiency virus/
acquired immune deficiency syndrome (HIV/AIDS) [44].
In addition to the broad-spectrum activity study described
above, strains of MRSA (MRSA 1, 2, and 3) were employed as a
multi-drug-resistant bacterium, for which susceptibility to a
reference peptide, LL-37, and to the selected HDAMPs (1, 3, 5,
and 6), having antimicrobial and anti-inflammatory activities, were
tested. Surprisingly, our selected HDAMPs were found to cause a
two-fold increase in activity against the methicillin-resistant strains
than against the normal S. aureus, whereas LL-37 showed an
increase in the level of MIC values (Table 2).
Resistance to proteolytic degradation
To further assess the potential of HDAMPs as drug candidates
in peptide drug development, in vitro proteolytic stability has been
investigated in human blood plasma using selected HDAMPs.
Owing to the presence of several basic residues, AMPs are in fact
highly susceptible to trypsin. As shown in Figure 5, HDAMPs 1, 3,
5, and 6 preserved their antimicrobial activity in the presence of
trypsin after an incubation period of 24 h, while LL-37 and
melittin (a cytotoxic AMP from bee venom) completely lost their
antimicrobial activities. Additionally, the percentage of remaining
peptides at each degradation time was examined using analytical
RP-HPLC chromatograms after the trypsin treatment. Unlike
melittin and LL-37, HDAMPs 1, 3, 5, and 6 were fully resistant to
proteolysis by trypsin using RP-HPLC analysis (Figure 6).
Antimicrobial mechanism study
Several AMPs have been extensively studied to elucidate their
mode of antimicrobial action. To investigate the mechanism of
action of the HDAMPs and the contribution of His derivatives
with hydrophobic pendant alkyl tails on antibacterial activity, we
performed the following detailed biochemical methods.
Confocal laser-scanning microscopy
To investigate the action site of HDAMP-1, fluorescein
isothiocyanate (FITC)–labeled HDAMP-1 or buforin-2 was
incubated with log-phase E. coli (KCTC 1682) or S. aureus (KCTC
1621), and their localization was visualized by confocal laser-
scanning microscopy. As expected, buforin-2 penetrated the
bacterial membrane without cell damage and accumulated in
the cytoplasm of bacteria. In contrast, HDAMP-1 was unable to
translocate the bacterial membrane. This finding indicates that the
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major site of action of HDAMP-1 is the bacterial membrane
(Figure 7).
Membrane depolarization
To evaluate the effects of HDAMP-1 on S. aureus (KCTC 1621)
cytoplasmic membranes, the membrane potential-sensitive fluo-
rescent dye diSC3-5 was used. DiSC3-5 is distributed between the
cells and medium, depending on the cytoplasmic membrane
potential, and self-quenches when concentrated inside bacterial
cells. If the membrane is depolarized, the probe will be released
into the medium, causing a measurable increase in fluorescence.
Similar to melittin and LL-37, HDAMP-1 induced a complete
membrane depolarization under 26MIC (8 mg/mL). In contrast,
buforin-2 caused no or less membrane depolarization (Figure 8).
Dye leakage
Next, the ability of HDAMP-1 to cause leakage of a fluorescent
dye entrapped within the large unilamellar vesicles (LUVs)
composed of negatively charged phosphatidylethanolamine (PE)/
phosphatidylglycerol (PG) (7:3, w/w) was tested. HDAMP-1
induced very low (less than 30%) calcein leakage at 16 mg/mL
(Figure 9). This relatively lower calcein leakage from LUVs
suggests that HDAMP-1 may act by forming pores, instead of
rupturing the bacterial membrane.
Transmission electron microscopy
Finally, to study the morphological changes caused by the
action of HDAMPs, E. coli and S. aureus were incubated with
HDAMP-1, -5, and -6, and investigated by TEM. In comparison
to the untreated control, an obvious change of the cellular
structure was observed when HDAMPs were added (Figure 10).
The release of internal materials was clearly visible by the
treatment of HDAMPs, whereas the structures of untreated cells
were preserved without any indication of cell damage.
Discussion
Increased microbial drug resistance and the detrimental effects
of an excessive inflammatory response have generated a global
requirement for antimicrobial agents with dual functions.
Figure 3. The inhibitory effect of the indicated peptides in RAW264.7 cells. Cells were stimulated with LPS (20 ng/mL). (A–B) Inhibitory
activity against NO production in LPS-stimulated RAW264.7 cells. (A) Cells were treated with 8 mg/mL of each peptide. (B) Cells were treated with 0.5,
1, 2, 4, and 8 mg/mL of HDAMP-1, HDAMP-3, HDAMP-5, HDAMP-6, and LL-37. The cell-culture medium was collected, and the amount of nitrite
released was measured. (C–D) The effects of the peptides on TNF-a release in LPS-stimulated RAW264.7 cells. (C) Cells were treated with 16 mg/mL of
each peptide. (D) Cells were treated with 2, 4, 8, and 16 mg/mL of HDAMP-1 and LL-37. After incubation, the TNF-a concentration in the cell medium
was evaluated using a mouse TNF-a ELISA kit. Data shown are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0080025.g003
Figure 4. Concentration-response curves of LPS neutralization
by the peptides, as determined by LAL assay. Peptides are
indicated as follows: HDAMP-1 (N), HDAMP-3 (#), HDAMP-5 (.),
HDAMP-6 (h), and LL-37 (&).
doi:10.1371/journal.pone.0080025.g004
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In the present study, we focused on two areas. In the first part,
we investigated how the shortest designed HDAMPs affected
antimicrobial activity via systematic tuning of hydrocarbon tail
length, charge, hydrophobicity, and stereo specificity. While this
part was mostly a phenomenological description of the trends
observed in the hemolytic and antimicrobial activities of these
short, highly potent HDAMPs, the second section discussed the
anti-inflammatory activity evaluated by examining HDAMP
inhibition of NO, TNF-a production in LPS-stimulated
RAW264.7 cells, and direct LPS neutralization. The second
section also summarized the dual functionality of HDAMPs. Here,
we utilized the two non-equivalent, but similarly reactive, nitrogen
atoms on His, designed N(p) and N(t), to generate the focused
derivatives with pendant dialkylated tails, which was an effective
method for obtaining both potent antimicrobial and anti-
inflammatory activities. Notably, we have obtained the His-
derived amino acids in high yield via a simple, three-step synthetic
procedure (Figure 1).
Some of our designed HDAMPs exhibited potent broad-
spectrum antimicrobial activity, with improved prokaryotic
selectivity, and retained LPS neutralization activity in comparison
to LL-37. In particular, HDAMP-1 showed promising antimicro-
bial activity (GM: 3.5 mg/mL), which was 10 times higher than
LL-37 (GM: 36 mg/mL) and 10 times higher than the low HC10
(36 mg/mL) value against human erythrocytes. The results from
the antimicrobial assay and hemolysis experiments indicate that by
reducing the hydrophobicity of the peptide, the prokaryotic
selectivity was enhanced as expected. Interestingly, HDAMPs (2,
4, and 5) were non-hemolytic and possessed higher therapeutic
index values than the non-hemolytic LL-37 (Table 1). The
structure–activity relationship (SAR) in this series of ultra-short
peptides revealed that the maximum potencies and spectra of the
antimicrobial activities correlated with the presence of one His,
having a pendant alkyl tail (hydrophobicity), a lengthy carbon
chain of pendant alkyl tails, an optimum number of Arg residues
(cationicity), and stereospecificity (L-form preferred over D-Arg).
Strong evidence that HDAMP showed anti-inflammatory
activity was obtained from the surprising inhibition of HDAMPs,
such as 1, 3, 5, and 6, against NO, TNF-a production in the LPS-
stimulated RAW 264.7 cells (Figure 3), and a mouse macrophage
cell line. It is interesting to note the HDAMP-3, which has a
higher hydrophobicity among HDAMPs, is less active than
HDAMP-1. This difference in the anti-inflammatory activity led
us to speculate that rather than global hydrophobicity, explicit
involvement of the Arg stereochemical arrangement may be
important for anti-inflammatory activity.
Table 2. Antimicrobial activity of designed HDAMPs against methicillin-resistant Staphylococcus aureus strains.
Peptides Minimal Inhibitory Concentration (MIC)
a
MRSA 1 [CCARM 3089] MRSA 2 [CCARM 3090] MRSA 3 [CCARM 3095]
HDAMP-1 2 (2.5) 2 (2.5) 2 (2.5)
HDAMP-2 16 (22.7) 32 (45.5) 16 (22.7)
HDAMP-3 2 (3) 2 (3) 2 (3)
HDAMP-4 16 (24.9) 16 (24.9) 16 (24.9)
HDAMP-5 8 (9.8) 8 (9.8) 8 (9.8)
HDAMP-6 2 (3) 2 (3) 2 (3)
LL-37 .32 (.7.1) .32(.7.1) .32(.7.1)
aMinimal inhibitory concentration of peptides in mg/mL; values in parentheses are in mM.
doi:10.1371/journal.pone.0080025.t002
Figure 5. Inhibition of peptide antimicrobial activity against E. coli (KCTC 1682) by trypsin, assessed using the radial diffusion
assay.
doi:10.1371/journal.pone.0080025.g005
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Finally, the HDAMPs, having the combination of antimicrobial
and anti-inflammatory properties, were subjected to the anti-
MRSA assay and trypsin-based proteolytic degradation to
investigate the potential for their therapeutic application. Re-
markably, the result of the anti-MRSA assay suggested that the
selected shortest HDAMPs (1, 3, 5, and 6) overcame the
development of MRSA resistance in comparison to LL-37
(Table 2). Moreover, the stability data clearly showed that our
His derivatives, having hydrophobic pendant alkyl tails, gave the
HDAMPs greater protease stability beyond the additive contribu-
tion of the individual D-Arg amino acids (Figures 5 and 6). In
addition, based on the mechanistic studies (Figures 7–10), we
propose here that HDAMP-1 kills microorganisms via dissipation
of the membrane potential by forming pore/ion channels on
bacterial cell membranes (barrel stave model or toroidal model),
and not via the membrane-disruption/perturbation modes (car-
pet-like model). Although many problems still need to be solved,
the undesirable properties of AMPs that stem from MRSA
resistance, protease stability, and immunogenicity could be
overcome with these ultra-short HDAMPs.
We demonstrated the first synthesis of the shortest HDAMPs,
having diverse structural scaffolds obtained by facile chemical
tailoring, which provides potent antimicrobial and anti-inflamma-
tory activities, as well as enhanced bioavailability due to high water
solubility and protease stability. Some of our designed ultra-short
HDAMPs (1, 3, 5, and 6) exhibited not only high antimicrobial
activity against Gram-positive and Gram-negative bacterial
strains, including MRSA, with no or less hemolytic activity, but
also significantly inhibited NO and/or TNF-a release in LPS-
stimulated immune cells and neutralized LPS. Moreover, we
showed the systematic comparison of common structural param-
eters of HDAMPs, such as charge, hydrophobicity, and length,
which are important for the comprehensive understanding of how
peptides kill pathogens. Considering all these things, our
HDAMPs have given us a new strategy for overcoming the main
hurdles of AMPs, including chain length, limited stability,
solubility, MRSA resistance, and mass production, which have
limited their development into therapeutic agents.
Materials and Methods
Rink amide 4-methylbenzhydrylamine (MBHA) resin and 9-
fluorenylmethoxycarbonyl (Fmoc) amino acids were obtained from
Calbiochem-Novabiochem (La Jolla, CA). Other reagents used for
peptide synthesis included trifluoroacetic acid (TFA; Sigma),
piperidine (Merck), dicyclohexylcarbodiimide (DCC; Fluka), 1-O-
Benzotriazole-N,N,N9,N9-tetramethyl-uronium-hexafluoro-phos-
phate (HBTU; Aldrich), 1-hydroxybenzotriazole (HOBT; Al-
drich), N,N-diisopropylethylamine (DIEA; Aldrich) and dimethyl-
formamide (DMF, peptide synthesis grade; Biolab).
Lipopolysaccharide (LPS, from E. coli O111:B4) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) were supplied from Sigma Chemical Co (St. Louis, MO).
DMEM and fetal bovine serum (FBS) were obtained by HyClone
Figure 6. Proteolytic stability profiles of the designed HDAMPs, LL-37 and melittin, by trypsin. The relative concentrations of soluble
peptides were analyzed by the integration of the absorbance at 224 nm of the peaks from analytical RP-HPLC chromatograms.
doi:10.1371/journal.pone.0080025.g006
Figure 7. Confocal laser-scanning microscopic images of peptide-treated E. coli (KCTC 1682) or S. aureus (KCTC 1621) cells. (A) E. coli
treated with FITC-labeled HDAMP-1 or buforin-2 at 5 mg/mL, and (B) S. aureus treated with FITC-labeled HDAMP-1 or buforin-2 at 5 mg/mL. For each
fluorescence treatment, DIC and merge images have been presented.
doi:10.1371/journal.pone.0080025.g007
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(Seoulin, Bioscience, Korea). RAW264.7 cells were purchased
from American Type Culture Collection (Bethesda, MD).
Phosphatidylethanolamine (PE, from egg yolk), phosphatidylgly-
cerol (PG, from egg yolk), and calcein were purchased from Sigma
(St. Louis, MO). DiSC3-5 was obtained from Molecular Probes
(Eugene, OR). All other reagents were of analytical grade. The
buffers were prepared in double glass–distilled water.
Synthesis and characterization of HDAMPs
All peptides were prepared by Fmoc SPPS methods using Rink
amide with an initial loading of 0.61 mmol/g, unless otherwise
noted. Fmoc-Arg(Pbf)-OH and other Fmoc-protected amino acids
were purchased from Novabiochem. Resins were swollen in DMF
for 45 min prior to synthesis. For sequence extension, the Fmoc-
protected amino acid (5 eq.) was activated by treatment with
HBTU (5.0 eq.), 1-hydroxybenzotriazole (HOBt; 5.0 eq.), and
DIEA (10 eq.) in DMF (2 mL) for 2 min. This solution was added
to the free amine on resin, and the coupling reaction was allowed
to proceed for 1 h with vortex stirring. After washing with DMF,
Fmoc de-protection was achieved with 20% piperidine in DMF
(1610 min, 263 min). The resin was washed once again, and the
process was repeated for the next amino acid; finally, the resin was
washed with DMF, methanol, dichloromethane, and ether, and
then dried under a vacuum. In the case of FITC-labeled peptides,
Fluorescein 5-isothiocyanate (2 eq.) was added in DMF, along with
the DIEA (4 eq.), to the N-terminal free amine on resin, and the
coupling was allowed to proceed overnight with vortex stirring. All
the peptides were cleaved from the resin with 5% triisopropylsi-
lane (TIS) and 5% H2O in trifluoroacetic acid (TFA, approxi-
mately 2 mL of TFA per 100 mg of resin) for 2 h. The cleavage
mixture was mixed with cold ether to precipitate the peptide, and
then filtered. RP-HPLC analysis was carried out on the prepared
Vydac C18 column (15 mm, 20 mm 6250 mm), using an
appropriate 0290% water/acetonitrile gradient in the presence
of 0.05% TFA. The final purity and hydrophobicity of the
peptides (.98%) were assessed by RP-HPLC on an analytical
Vydac C18 column (4.6 mm 625 0 mm, 300 Å, 5 mm particle
size, Table 3). The molecular masses of purified peptides were
determined using MALDI-TOF MS (Shimadzu, Japan).
General procedure for the preparation of N (a)-[(9H-
Fluoren-9-ylmethoxy)carbonyl]-N(p)-,N(t)-bisalkyl-L-
histidine. The synthesis was performed in accordance
with Qian et al [39]
Compound B: (Figure 1)
A 100-mL Schlenk flask was charged with solid Fmoc-His(Trt)-
OH (10 g, 16.14 mmol) and HOBt (3.27 g, 24.20 mmol), and was
degassed by vacuum-Ar purge cycle. Dry THF (80 mL) was added
to dissolve all solids, and the solution was cooled to -13uC with an
ice-acetone bath. A dry THF solution (80 mL) of DCC (3.33 g,
16.14 mmol) was added to this mixture dropwise, along with
MeOH, (12.40 mL, 513.0 mmol). The reaction was allowed to
warm slowly to room temperature while stirring overnight, during
which time solid dicyclohexylurea was observed to precipitate.
This was removed by vacuum filtration through a medium-
porosity frit, and the solvent was removed by rotary evaporation.
Figure 8. Time-dependent, peptide-induced cytoplasmic membrane depolarization against S. aureus (KCTC 1621, OD600 = 0.05).
Membrane depolarization was measured by an increase in fluorescence of the membrane potential–sensitive dye, diSC3-5. Dye release was
monitored at an excitation wavelength of 622 nm and an emission wavelength of 670 nm. In each run, the peptides were added near the 400-s mark.
doi:10.1371/journal.pone.0080025.g008
Figure 9. Time-dependent, peptide-induced dye leakage from
calcein-entrapped, negatively charged PE/PG (7:3, w/w) LUVs.
doi:10.1371/journal.pone.0080025.g009
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The oily residue was re-dissolved in dichloromethane, washed
three times with aqueous NaHCO3, and washed three times with
water, and the organic layer was dried over MgSO4. The solvent
was removed by rotary evaporation, and a crude yellow solid was
isolated after drying. The compound was purified by column
chromatography on silica gel and eluted with 1% MeOH-DCM
(10.34 g, quantitative yield) Rf = 0.33
1H-NMR (300 MHz, CDCl3): d 7.75 (d, 2H, J = 7.5 Hz), 7.62
(t, 2H, J = 7.5 Hz), 7.53 (s, 1H), 7.42–7.26 (m, 13H), 7.13–7.10
(m, 6H), 6.57 (s, 1H), 6.53 (d, 1H, J = 8.2 Hz), 4.63 (m, 1H), 4.38–
4.22 (m, 3H), 3.63 (s, 3H), 3.13–3.03 (m, 2H). All the values are in
agreement with the reported values [45].
Synthesis of N (a)-[(9H-Fluoren-9-ylmethoxy)carbonyl]-
N(p)-,N(t)-bis(7-phenylheptyl)-L-histidine methyl ester
(Compound C1)
A solution of 7-phenyl-1-heptanol (1.12 mL, 5.58 mmol) and
diisopropylethylamine (DIEA) (973 mL, 5.58 mmol) in DCM
(50 mL), added dropwise over 10 min, was added to a stirred
solution of triflic anhydride (939 mL, 5.58 mmol) in DCM (35 mL)
under Ar at 275uC. Stirring was continued at 275uC (20 min);
then, a solution of FmocHis(Trt)-OMe (1.77 g, 2.79 mmol) in
DCM (25 mL) was added dropwise, and the mixture was allowed
to gradually warm to room temperature over a period of 18 h.
The mixture was quenched using aqueous NaHCO3 and stirred
vigorously (30 min). The organic layer was diluted with DCM and
washed with aqueous NaHCO3 and brine, then dried (MgSO4),
and concentrated to viscous oil. Trifluoroacetic acid (2 mL,
27.90 mmol) and TIS (629 mL, 3.07 mmol) were added to a
solution of the resulting gum in DCM (25 mL), and the mixture
was stirred at room temperature until the reaction was complete,
as shown by TLC (2 h). The solvent was removed in vacuo, and
the residue was purified by silica gel column chromatography
using 1–5% MeOH in DCM to provide the product as a pale,
yellow gum (1.73 g, 85% yield). Note that although the in situ–
generated triflates will remove the trityl-protecting group from the
histidine, we treated again with TFA in order to make sure the
trityl group was completely removed from either the minor
monoalkylated or unknown product, for a better purification
process.
lH-NMR (300 MHz, CDCl3): d 8.91 (s, 1H), 7.77 (d,
J = 7.4 Hz, 2H), 7.57–7.68 (m, 2H), 7.23–7.08 (m, 14H), 6.23
(br. s, 1H), 4.60 (m, 1H), 4.37 (d, J = 6.0 Hz, 2H), 4.21 (t,
J = 6.9 Hz, 1H), 3.99–4.15 (m, 4H), 3.78 (s, 3H), 3.17–3.30 (m,
3H), 2.53–2.67 (m, 4H), 1.69–1.78 (m, 3H), 1.47–1.66 (m, 5H),
1.38–1.47 (m, 3H), 1.23 (s, 9H).
Synthesis of N (a)-[(9H-Fluoren-9-ylmethoxy)carbonyl]-
N(p)-,N(t)-bis(7-phenylheptyl)-L-histidine (Compound
D1)
The 1:1 mixture of 2 N HCl (50 mL) and 1,4-Dioxane (50 mL)
solution was added to the C1 (1.6 g, 2.20 mmol), and reflux
occurred at 100uC for 3 h. The mixture was brought to room
temperature, and the solvent was removed by Rota vapor. The
resulting aqueous mixture was extracted with DCM, washed with
brine, dried (MgSO4), and concentrated to viscous oil. The
organic extract was dried (MgSO4) and concentrated in vacuo,
and the residue was purified by silica gel–flash chromatography
from 5% to 20% MeOH in DCM to provide the acid as a light
yellow gum (0.69 g, 43% yield).
lH-NMR (300 MHz, CDCl3): d 8.47 (s, 1H), 7.72 (d,
J = 7.4 Hz, 2H), 7.52–7.68 (m, 2H), 7.08–7.43 (m, 14H), 6.83
(m, 1H), 4.34 (m, 1H), 4.03–4.28 (m, 3H), 3.82–4.03 (m, 2H),
3.49–3.73 (m, 2H), 2.98–3.33 (m, 2H), 2.35–2.72 (m, 4H), 1.59–
1.89 (m, 4H), 1.41–1.59 (m, 4H), 1.21 (s, 12H).
13C-NMR (75 MHz, CDCl3): d 172.5, 156.2, 143.9, 143.3,
142.6, 142.5, 141.3, 141.2, 134.6, 131.2, 128.4, 128.3, 127.9,
Figure 10. Electron micrographs of negatively stained E. coli and S. aureus, untreated or treated with HDAMPs. All images are scaled,
and the scale bar represents 1 mm.
doi:10.1371/journal.pone.0080025.g010
Table 3. RP-HPLC retention time of the indicated HDAMPs.







RP-HPLC retention time (Rt) was measured using a C18 reverse-phase analytical
column (5 mm; 4.6 mm 6250 mm; Vydac). Peptides were eluted for 60 min
using a linear gradient of 0–90% (v/v) acetonitrile in water containing 0.05% (v/
v) trifluoroacetic acid.
doi:10.1371/journal.pone.0080025.t003
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127.2, 125.7, 125.3, 125.0, 121.3, 120.0, 67.0, 53.6, 49.9, 47.3,
46.9, 35.8, 31.2, 31.1, 29.9, 29.8, 28.9, 28.7, 28.6, 26.2, 26.0, 24.8.
MS (MALDI-TOF) m/z 726.43[M]+.
Synthesis of N (a)-[(9H-Fluoren-9-ylmethoxy)carbonyl]-
N(p)-,N(t)-bis(3-phenylpropyl)-L-histidine methyl ester
(Compound C2)
The title compound was synthesized in a manner identical to
compound C1, using 3-phenylpropanol (709 mL, 5.21 mmol)
instead of 7-phenyl-1-heptanol. Materials: Fmoc-His(Trt)-OMe
(1.5 g, 2.37 mmol, 20 mL DCM), Tf2O (877 mL, 3.16 mmol,
35 mL DCM), DIEA (911 mL, 5.21 mmol, 45 mL DCM), TFA
(1.8 mL, 23.70 mmol), and TIPS (534 mL, 2.61 mmol, 20 mL
DCM). The compound is purified by column chromatography on
silica gel, eluted with 1–5% MeOH-DCM. 1.33 g, 89% yield.
lH-NMR (300 MHz, CDCl3): d 8.91 (s, 1H), 7.80 (d,
J = 7.4 Hz, 2H), 7.56–7.70 (m, 2H), 7.04–7.49 (m, 14H), 6.63
(d, J = 7.6 Hz, 1H), 4.49 (m, 1H), 3.97–4.39 (m, 7H), 3.76 (s, 3H)
3.15 (s, 2H), 2.70 (t, J = 7.14 Hz, 2H), 2.59 (t, J = 7.1 Hz, 2H),
2.20–2.04 (m, 4H).
Synthesis of N (a)-[(9H-Fluoren-9-ylmethoxy)carbonyl]-
N(p)-,N(t)-bis(3-phenylpropyl)-L-histidine (Compound
D2)
The title compound was synthesized in a manner identical to
compound D1, using C2 instead of C1 (1.33 g, 2.11 mmol).
Materials: 2 N HCl: 1,4-Dioxane (45 mL: 45 mL). The com-
pound was purified by column chromatography on silica gel,
eluted with 5–20% MeOH-DCM. 0.87 g, 67% yield.
lH-NMR (300 MHz, CDCl3): d 8.43 (s, 1H), 7.69 (d,
J = 7.1 Hz, 2H), 7.52–7.59 (dd, J = 6.5 Hz, J = 9.0 Hz, 2H),
7.34 (t, J = 7.4 Hz, 2H), 7.03–7.28 (m, 12H), 6.61 (m, 1H), 4.18–
4.33 (m, 2H), 4.01–4.18 (m, 4H), 3.88–4.01 (m, 2H), 3.01–3.24 (m,
2H), 2.45–2.69 (m, 4H), 1.93–2.16 (m, 4H).
13C-NMR (75 MHz, CDCl3): d 173.2, 156.5, 144.3, 144.0,
141.7, 140.0, 139.9, 135.6, 132.4, 129.0, 128.7, 128.6, 128.2,
127.5, 126.8, 125.5, 125.4, 120.4, 67.2, 54.4, 49.6, 47.5, 47.1,
34.3, 32.8, 32.7, 31.55, 31.45, 26.6, 25.4, 25.3.
MS (MALDI-TOF) m/z 614.30[M]+.
Synthesis of N (a)-[(9H-Fluoren-9-ylmethoxy) carbonyl]-
N(p)-(7-phenylheptyl)-L-histidine methyl ester
(Compound C3)
A solution of 7-phenyl-1-heptanol (526 mL, 2.63 mmol) and
diisopropylethylamine (DIEA) (458 mL, 1.11 mmol) in DCM
(15 mL), added dropwise over 10 min, was added to a stirred
solution of triflic anhydride (443 mL, 1.11 mmol) in DCM (15 mL)
under Ar at 275uC. Stirring was continued at 275uC (20 min).
Then, a solution of FmocHis(Trt)-OMe (1.5 g, 2.37 mmol) in
DCM (20 mL) was added dropwise, and the mixture was allowed
to gradually warm to room temperature over a period of 16 h.
The mixture was quenched using aqueous NaHCO3 and stirred
vigorously (30 min). The organic layer was diluted with DCM,
washed with aqueous NaHCO3 and brine, dried (MgSO4), and
concentrated to viscous oil. Trifluoroacetic acid (1.68 mL,
23.70 mmol) and TIS (507 mL, 2.48 mmol) were added to a
solution of the resulting gum in DCM (15 mL), and the mixture
was stirred at room temperature until the reaction was complete,
as shown by TLC (2 h). The solvent was removed in vacuo, and
the residue was purified by silica gel–column chromatography
using 1–5% MeOH in DCM to provide the product as a colorless
gum (0.87 g, 65% yield).
lH-NMR (300 MHz, CDCl3): d 8.48 (s, 1H), 7.77 (d,
J = 7.5 Hz, 2H), 7.57 (d, J = 7.0 Hz, 2H), 7.16–7.43 (m, 9H),
6.86 (s, 1H), 4.39 (m, 1H), 3.79–4.30 (m, 5H), 3.69 (s, 3H), 3.16 (s,
2H), 2.61 (t, J = 7.4 Hz, 2H), 1.67–1.86 (m, 2H), 1.47–1.66 (m,
2H), 1.32 (s, 6H).
MS (MALDI-TOF) m/z 566.14 [M]+.
Synthesis of N (a)-[(9H-Fluoren-9-ylmethoxy) carbonyl]-
N(p)-(7-phenylheptyl)-L-histidine (Compound D3)
The 1:1 mixture of 2 N HCl (20 mL) and 1,4-Dioxane (20 mL)
solution was added to the C3 (0.64 g, 1.13 mmol), and reflux
occurred at 100uC for 3 h. The mixture was brought to room
temperature, and the solvent was removed by Rota vapor. The
resulting aqueous mixture was extracted with DCM, washed with
brine, dried (MgSO4), and concentrated to viscous oil. The
organic extract was dried (MgSO4) and concentrated in vacuo,
and the residue was purified by silica gel–flash chromatography
from 5% to 20% MeOH in DCM to provide the acid as a light
yellow gum (0.50 g, 80% yield).
lH-NMR (300 MHz, CDCl3): d 8.41 (s, 1H), 7.72 (d,
J = 7.0 Hz, 2H), 7.46–7.63 (m, 2H), 7.30–7.43 (m, 2H), 7.07–
7.40 (m, 9H), 6.51 (m, 1H), 4.56 (m, 1H), 4.22–4.37 (m, 2H),
4.11(m, 1H), 3.85–4.10 (m, 2H), 3.13–3.38 (m, 2H), 2.43–2.60 (m,
2H), 1.60–1.77 (m, 2H), 1.40–1.59 (m, 2H), 1.20 (s, 6H).
13C-NMR (75 MHz, CDCl3): d 176.1, 156.1, 144.4, 144.0,
143.1, 141.6, 134.7, 131.7, 128.7, 128.6, 128.1, 127.4, 125.9,
125.8, 120.4, 120.0, 66.9, 55.8, 47.4, 46.9, 36.2, 31.7, 30.4, 29.6,
29.5, 29.3, 26.7.
MS (MALDI-TOF) m/z 552.12 [M]+.
AMP: (WR)3-NH2
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 18.53 min (gradient B: 5–90%/
30 min); MS (MALDI-TOF) m/z 1044.39 [M + H]+.
AMP: (WR)2-NH2
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 17.27 min (gradient B: 5–90%/
30 min); MS (MALDI-TOF) m/z 702.29 [M + H]+.
AMP: RWR-NH2
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 13.62 min (gradient B: 5–90%/
30 min); MS (MALDI-TOF) m/z 516.29 [M + H]+.
Tetrameric HDAMP: DRDR-amide (where D = 1, histidine
derivative)
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 37.7 min (linear gradient B, 0–
90%/60 min); MS (MALDI-TOF) m/z 1300.96 [M]+.
HDAMP-1, RDR-amide (where D = 1, histidine derivative)
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 29.21 min (linear gradient B, 0–
90%/60 min); MS (MALDI-TOF) m/z 815.60 [M]+.
HDAMP-2, RDR-amide (where D = 2, histidine derivative)
The purity of the crude product was 95% (C18 RP-
HPLC).White powder; RP-HPLC Rt = 21.32 min (linear gradient
B, 0–90%/60 min); MS (MALDI-TOF) m/z 703.50 [M]+.
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HDAMP-3, DR-amide (where D = 1, histidine derivative)
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 31.05 min (linear gradient B, 0–
90%/60 min); MS (MALDI-TOF) m/z 659.57 [M]+.
HDAMP-4, RDR-amide (where D = 3, histidine derivative)
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 21.77 min (linear gradient B, 0–
90%/60 min); MS (MALDI-TOF) 641.42 [M + H]+.
HDAMP-5, RDR-amide (where D = 1, histidine derivative,
R = D-Arg)
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 28.91 min (linear gradient B, 0–
90%/60 min); MS (MALDI-TOF) 816.66 [M]+.
HDAMP-6, DR-amide (where D = 1, histidine derivative,
R = D-Arg)
The purity of the crude product was 95% (C18 RP-HPLC).
White powder; RP-HPLC Rt = 30.78 min (linear gradient B, 0–
90%/60 min); MS (MALDI-TOF) 659.62 [M]+.
FITC-labeled HDAMP-1
The purity of the crude product was 90% (C18 RP-HPLC).
Rt = 41.35 (linear gradient, 0–90% B, 60 min); MS (MALDI-
TOF) m/z = 1205.72 [M+H]+.
Antimicrobial activity (MIC)
The antimicrobial activity of the peptides against two Gram-
positive bacterial strains and two Gram-negative bacterial strains
was examined using the broth microdilution method in sterile 96-
well plates. Aliquots (100 mL) of a bacterial suspension at 26106
colony-forming units (CFU)/mL in 1% peptone were added to
100 mL of the peptide solution (serial two-fold dilutions in 1%
peptone). After incubation for 18220 h at 37uC, bacterial growth
inhibition was determined by measuring the absorbance at
600 nm with a Microplate Autoreader EL 800 (Bio-Tek Instru-
ments, VT). The minimal inhibitory concentration (MIC) was
defined as the minimum peptide concentration inhibited bacteria
growth. Two types of Gram-positive bacteria (S. epidermidis [KCTC
1917] and S. aureus [KCTC 1621]) and two types of Gram-
negative bacteria (E. coli [KCTC 1682] and P. aeruginosa [KCTC
1637]) were procured from the Korean Collection for Type
Cultures (KCTC) at the Korea Research Institute of Bioscience
and Biotechnology (KRIBB). MRSA samples (CCARM 3089,
CCARM 3090, and CCARM 3095) were obtained from the
Culture Collection of Antibiotic-Resistant Microbes (CCARM) at
Seoul Women’s University (Seoul, Korea).
Ethics Statement
This study was approved by the institutional ethics committee,
and all healthy donors provided written informed consent before
treatment. Consequently, we processed the blood samples
according to the ethical standards of the Institutional Ethics
Committee of Chosun University and according to the checklist
for ethical consideration of cytotoxicity studies (https://www.cre.
or.kr/article/policy/1382313). The collection of the human red
blood cells (RBCs) from healthy donors was conducted at the
Chosun University Hospital in Kwangju (Republic of Korea).
Moreover, this study received ethics approval from the Institu-
tional Ethics Committee of Chosun University. The authors of this
article were blinded to all personal data from the donors, and all
blood donors remained anonymous. All procedures were carried
out according to rules provided by the Institutional Ethics
Committee of Chosun University. Samples of blood were obtained
from five healthy donors. The samples were stored immediately at
4uC until needed [41].
Hemolytic activity
Hemolytic activity of peptides was tested against hRBCs. Fresh
hRBCs were washed three times with phosphate-buffered saline
(PBS; 35-mM phosphate buffer containing 150 mM of NaCl,
pH 7.4) by centrifugation for 10 min at 10006g and then re-
suspended in PBS. The peptide solutions (serial two-fold dilutions
in PBS) were then added to 100 mL of hRBCs in PBS to give a
final volume of 200 mL and a final erythrocyte concentration of
4% (v/v). The resulting suspension was incubated with agitation
for 1 h at 37uC. The samples were then centrifuged at 10006g for
5 min, and hemoglobin release was monitored by measuring the
absorbance of the supernatant at 405 nm. No hemolysis (blank)
and 100% hemolysis controls consisted of hRBCs suspended in
PBS and 0.1% Triton X-100, respectively. Percent hemolysis was
calculated using the following equation:
Hemolysis (%)~½(OD405nm sample{OD405nm zero lysis)
=(OD405nm 100 % lysis{OD405nm zero lysis) | 100:
Quantification of nitrite production in LPS-stimulated
RAW264.7 cells
Nitrite accumulation in culture media was used as an indicator
of NO production [46]. RAW264.7 cells were plated at a density
of 56105 cells/mL in 96-well culture plates, and were stimulated
with LPS (20 ng/mL) from E. coli O111:B4 (Sigma) in the
presence or absence of peptides for 24 h. Isolated supernatant
fractions were mixed with an equal volume of Griess reagent (1%
sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride,
and 2% phosphoric acid) and incubated at room temperature
for 10 min. Nitrite production was determined by measuring
absorbance at 540 nm and converted to nitrite concentrations by
reference to a standard curve generated with NaNO2.
Quantification of TNF-a production by ELISA in LPS-
stimulated RAW 264.7 cells
An antibody against mouse tumor necrosis factor-a (mTNF-a)
was immobilized on immuno-plates by incubating with 0.2–
0.8 mg/mL solutions of antibody in PBS overnight at room
temperature. Plates were washed once with PBS [0.1% Tween 20
(PBST)] and blocked by incubating with 200 mL of blocking
solution [3% bovine serum albumin (BSA), 0.02% NaN3 in PBS]
overnight at room temperature. The supernatants from LPS-
stimulated RAW264.7 cells co-incubated with serial-diluted
peptide for 18 h were added to the wells of pre-coated plates
and incubated for 2 h at room temperature. After washing plates
three times with PBST, biotinylated anti-mTNF-a antibody
(0.4 mg/mL), diluted in 0.1% BSA, was added, and plates were
incubated for 2 h. Plates were then washed three times with PBST
and further incubated with streptavidin peroxidase (0.3 mg/mL)
diluted in PBS. After washing, SureBlue 3,39,5,59-tetramethylben-
zidine peroxidase substrate (Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, MD) was added. The enzyme reaction was
allowed to proceed at room temperature for color development,
and was stopped by adding 100 mL of 1 M H2SO4. The
absorbance at 450 nm was detected using a microplate reader.
Development of Antimicrobial Peptidomimetics
PLOS ONE | www.plosone.org 13 November 2013 | Volume 8 | Issue 11 | e80025
All values represent the mean 6 S.D. of at least three independent
experiments [47].
LPS-neutralizing activity
The ability of the peptides to neutralize or inhibit LPS was
assessed using a commercially available LAL assay kit (Kinetic-
QCL 1000 kit; BioWhittaker, Walkersville, MD, USA). Briefly,
25 mL of serially diluted peptide was added in duplicate to 25 mL
of E. coli O55:B5 LPS containing 3.0 U/mL endotoxin for 30 min
at 37uC, followed by incubation with 50 mL of amoebocyte lysate
reagent for 10 min. Absorbance at 405 nm was measured 10 and
16 min after the addition of 100 mL of the chromogenic substrate,
Ac-Ile-Glu-Ala-Arg-p-nitroanilide. The amount of non-bound
LPS was extrapolated from a standard curve, and the percentage
of inhibition was calculated as: [(amount of free LPS in control
samples) 2 (amount of free LPS in test samples)]6100/amount of
free LPS in control samples.
Protease stability by radial diffusion assay
E. coli (KCTC 1682) was grown overnight for 18 h at 37uC in
10 mL of LB broth, and then 10 ml of this culture was inoculated
into 10 mL of fresh LB and incubated for an additional 3 h at
37uC to obtain mid-logarithmic-phase organisms. For the radial
diffusion assay method, a bacteria suspension (26106 CFU/mL in
LB) was mixed with 0.7% agarose. The mixture was poured into a
10-cm petri dish after rapidly dispersing. Five microliters of an
aqueous peptide stock solution (10 mg/mL) were added to 25 mL
of the 0.2-mg/mL trypsin solution in PBS, respectively, and
incubated at 37uC for 6 h. The reaction was stopped by freezing
with liquid nitrogen, and then 10-mL aliquots were placed in each
circle paper (<6 mm in diameter) put on the agarose plates and
then incubated at 37uC overnight. The diameters of the bacterial
clearance zones surrounding the circle paper were measured for
the quantitation of inhibitory activities.
Protease stability by RP HPLC
Five microliters of an aqueous peptide stock solution (10 mg/
mL) were added to 25 mL of the 0.2-mg/mL trypsin solution in
PBS, respectively, and incubated at 37uC for 0, 0.5, 1.0, 2.0, and
4 h. The 5-mL solution was taken out at each time interval and
immediately frozen with liquid nitrogen. Individually thawed
samples were loaded onto a C18 reverse-phase column for HPLC
analysis (5 mm; 4.6 mm 6250 mm; Vydac). Peptides were eluted
by a 60-min linear gradient of 0–90% (v/v) acetonitrile in water
containing 0.05% (v/v) trifluoroacetic acid with a flow rate of
1 mL/min and detection of 224 nm.
Morphological changes of bacteria after HDAMP addition
Morphological changes of a Gram-negative bacterial strain (E.
coli [KCTC 1682]) and a Gram-positive bacterial strain (S. aureus
[KCTC 1621]) after the addition of HDAMPs (HDAMP-1,
HDAMP-5, and HDAMP-6) were analyzed using TEM. The
bacterial culture at 26106 CFU/mL in LB media was washed
three times in PBS via a series of centrifugation at 10,0006 g, for
5 min, and re-suspension. One-hundred microliters of HDAMPs
in PBS were added to an equal volume of bacterial suspension to a
final concentration at 610 MIC. Following the addition of
HDAMPs, the samples were incubated for 1 h at 37uC. Bacterial
cell pellet after centrifugation was re-suspended in 20 ml PBS for
TEM specimen preparation. Five microliters of sample solution
were loaded onto a carbon film-coated TEM grid, which was
rendered hydrophilic by glow discharge. After 90 s, excess sample
solution was washed off with distilled water. Five microliters of 1%
uranyl acetate were loaded onto the grid for negative staining for
1 min, and excess stain solution was blotted using a piece of filter
paper. Samples were imaged using a Tecnai G2 Spirit electron
microscope (FEI) equipped with a lanthanum hexaboride (Lab6)
gun, operating at 120 kV. Images were recorded using the
Ultrascan 4000 charge-coupled device (CCD) camera (Gatan).
Confocal laser-scanning microscopy
E. coli (KCTC 1682) and S. aureus (KCTC 1621) cells in the mid-
logarithmic phase were harvested by centrifugation, washed three
times with a 10-mM phosphate buffer saline, pH 7.4. Bacteria
(107 CFU/mL) cells were incubated with FITC-labeled peptides
(5 mg/mL) at 37uC for 30 min. After being incubated, the
bacterial cells were pelleted down and washed three times with
the 10 mM sodium phosphate buffer, pH 7.4, and immobilized on
a glass slide. The FITC-labeled peptides were observed with a
Zeiss Axioplan 2 optical microscope (Japan). Fluorescent images
were obtained with a 488-nm band-pass filter for excitation of
FITC.
Membrane depolarization
The cytoplasmic membrane depolarization activity of peptides
was determined by the membrane potential–sensitive dye, diSC3-
5. Briefly, S. aureus was grown at 37uC with agitation to the mid-log
phase (OD600 = 0.4), and was harvested by centrifuge. The cells
were washed twice with washing buffer (20 mM glucose, 5 mM
HEPES, pH 7.4) and re-suspended to an OD600 of 0.05 in a
similar buffer containing 0.1 M KCl. Thereafter, the cells were
incubated with 20 nM of DiSC3-5 until a stable reduction of
fluorescence was achieved, indicating the incorporation of the dye
into the bacterial membrane. Membrane depolarization was then
monitored by observing the change in the fluorescence emission
intensity of the membrane potential–sensitive dye, DiSC3-5
(lex. = 622 nm, lem = 670 nm), after the addition of peptides. Full
dissipation of the membrane potential was obtained by adding
gramicidin D (final concentration of 0.2 nM).
Dye leakage
Calcein-entrapped LUVs (large unilamellar vesicles) composed
of PE/PG (7:3, w/w) were prepared by vortexing the dried lipid in
dye buffer solution (70 mM calcein, 10 mM Tris, 150 mM NaCl,
0.1 mM EDTA, pH 7.4). The suspension was subjected to 10
frozen-thaw cycles in liquid nitrogen and extruded 21 times
through polycarbonate filters (two stacked 100-nm pore-size filters)
with a LiposoFast extruder (Avestin, Inc. Canada). Untrapped
calcein was removed by gel filtration on a Sephadex G-50 column.
Calcein leakage from LUVs was monitored at room temperature
by measuring fluorescence intensity at an excitation wavelength of
490 nm and emission wavelength of 520 nm on a model RF-
5301PC spectrophotometer. Complete dye release was obtained
using 0.1% Triton X-100.
Abbreviations: AMP, antimicrobial peptide; MIC, minimal
inhibitory concentration; MRSA, methicillin-resistant Staphylococ-
cus aureus
Supporting Information
Figure S1 Concentration–response curves of percent
hemolysis of the peptides against human red blood cells.
Peptides are indicated as follows: (WR)3-NH2 ( ), (WR)2-NH2
(#), RWR-NH2 (.), HDAMP-1 (h), HDAMP-2 (&), HDAMP-3
(%), HDAMP-4 (X), HDAMP-5 (e), HDAMP-6 (m), and LL-
37(g).
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